Highland Capital Management Fund Advisors, L.P. Paratek Pharmaceuticals, Inc. Transaction History

Highland Capital Management Fund Advisors, L.P.

$846 Million
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.37 - $2.54 $3.26 Million - $6.05 Million	2,381,000 Added 2074.58%	2,495,770 $6.34 Million
Q4 2021 Feb 14, 2022	SELL	$4.07 - $5.3 $610,500 - $795,000	-150,000 Reduced 56.65%	114,770 $516,000
Q2 2021 Aug 16, 2021	BUY	$6.81 - $10.93 $885,300 - $1.42 Million	130,000 Added 96.46%	264,770 $1.81 Million
Q1 2021 May 17, 2021	SELL	$6.14 - $8.31 $32,235 - $43,627	-5,250 Reduced 3.75%	134,770 $951,000
Q2 2020 Aug 14, 2020	SELL	$2.97 - $5.22 $61,924 - $108,837	-20,850 Reduced 12.96%	140,020 $731,000
Q1 2020 May 15, 2020	SELL	$2.67 - $4.97 $2.15 Million - $4 Million	-805,623 Reduced 83.36%	160,870 $507,000
Q3 2019 Nov 14, 2019	BUY	$3.08 - $5.76 $2.98 Million - $5.57 Million	966,493 New	966,493 $4.18 Million

Others Institutions Holding PRTK

# of Institutions

Shares Held

1.54M

Call Options Held

Put Options Held

View Full List

About Paratek Pharmaceuticals, Inc.

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

More about PRTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Highland Capital Management Fund Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Highland Capital Management Fund Advisors, L.P. with notifications on news.

Account